Clinical Trial Details
— Status: Recruiting
Administrative data
NCT number |
NCT04637152 |
Other study ID # |
HGeralRobertoSantos |
Secondary ID |
|
Status |
Recruiting |
Phase |
Phase 2
|
First received |
|
Last updated |
|
Start date |
November 11, 2020 |
Est. completion date |
November 11, 2022 |
Study information
Verified date |
November 2020 |
Source |
Hospital Geral Roberto Santos |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
The present study aims to evaluate the antihypertensive effect of sacubitril/valsartan in
patients with resistant hypertension compared to the use of recommended and optimized
antihypertensive therapy, through a randomized clinical trial, over 12 weeks.
Description:
Worldwide, millions of people are affected by the arterial hypertension system (SAH), so that
the presence of resistant hypertension (RH) significantly influences a high cardiovascular
morbidity and mortality compared to those with controlled SAH, thus corroborating the need
for the development of agents antihypertensive drugs with favorable efficacy and safety
profiles. It is known that they are currently using the combined therapy recommended for this
group of patients, among them, a significant portion of individuals with RH are unable to
achieve the goal of BP control (>140/90 mmHg) even though in regular use, being subject to
the greatest risk of cardiovascular outcomes and morbidity and mortality. Approved by the FDA
for use in heart failure with reduced ejection fraction with beneficial effects on morbidity
and mortality, identified in previous studies, the sacubitril/valsartan molecule (LCZ696) or
Entresto® is a molecular complex composed of the sacubitril prodrug activated after ingestion
in sacubitrilate - neprilysin inhibitor - associated with valsartan, an angiotensin II type-1
(AT1) receptor antagonist, with vasodilating action, capable of reducing BP, sympathetic
tone, with antifibrotic and anti-hypertrophic effects, in addition to natriuresis and
diuresis. Considering the knowledge gap to the benefits to LCZ696 in the control of blood
pressure in resistant hypertension, the objective of the present study is to evaluate the
efficacy (reduction of ambulatory systolic and diastolic blood pressure) and safety (adverse
events, hospitalization and cardiovascular death) of the use of sacubitril/valsartan in
comparison to the antihypertensive therapy recommended and optimized by the current
guidelines, in patients diagnosed with RH, over12 weeks, through a randomized clinical trial.